Perspectives on Advancing Countermeasures for Filovirus Disease: Report From a Multisector Meeting

Abstract Although there are now approved treatments and vaccines for Ebola virus disease, the case fatality rate remains unacceptably high even when patients are treated with the newly approved therapeutics. Furthermore, these countermeasures are not expected to be effective against disease caused b...

Full description

Saved in:
Bibliographic Details
Published inThe Journal of infectious diseases Vol. 228; no. Supplement_7; pp. S474 - S478
Main Authors Sprecher, Armand, Cross, Robert, Marzi, Andrea, Martins, Karen A, Wolfe, Daniel, Montgomery, Joel M, Spiropoulou, Christina F, Cihlar, Tomas, Ahuka-Mundeke, Steve, Nyhuis, Tara, Teicher, Carrie, Crozier, Ian, Strong, Jim, Kobinger, Gary, Woolsey, Courtney, Geisbert, Thomas W, Feldmann, Heinz, Muyembe, Jean-Jacques
Format Journal Article
LanguageEnglish
Published United States Oxford University Press 15.11.2023
Subjects
Online AccessGet full text
ISSN0022-1899
1537-6613
1537-6613
DOI10.1093/infdis/jiad354

Cover

Loading…
Abstract Abstract Although there are now approved treatments and vaccines for Ebola virus disease, the case fatality rate remains unacceptably high even when patients are treated with the newly approved therapeutics. Furthermore, these countermeasures are not expected to be effective against disease caused by other filoviruses. A meeting of subject-matter experts was held during the 10th International Filovirus Symposium to discuss strategies to address these gaps. Several investigational therapeutics, vaccine candidates, and combination strategies were presented. The greatest challenge was identified to be the implementation of well-designed clinical trials of safety and efficacy during filovirus disease outbreaks. Preparing for this will require agreed-upon common protocols for trials intended to bridge multiple outbreaks across all at-risk countries. A multinational research consortium including at-risk countries would be an ideal mechanism to negotiate agreement on protocol design and coordinate preparation. Discussion participants recommended a follow-up meeting be held in Africa to establish such a consortium.
AbstractList Although there are now approved treatments and vaccines for Ebola virus disease, the case fatality rate remains unacceptably high even when patients are treated with the newly approved therapeutics. Furthermore, these countermeasures are not expected to be effective against disease caused by other filoviruses. A meeting of subject-matter experts was held during the 10th International Filovirus Symposium to discuss strategies to address these gaps. Several investigational therapeutics, vaccine candidates, and combination strategies were presented. The greatest challenge was identified to be the implementation of well-designed clinical trials of safety and efficacy during filovirus disease outbreaks. Preparing for this will require agreed-upon common protocols for trials intended to bridge multiple outbreaks across all at-risk countries. A multinational research consortium including at-risk countries would be an ideal mechanism to negotiate agreement on protocol design and coordinate preparation. Discussion participants recommended a follow-up meeting be held in Africa to establish such a consortium.
Although there are now approved treatments and vaccines for Ebola virus disease, the case fatality rate remains unacceptably high even when patients are treated with the newly approved therapeutics. Furthermore, these countermeasures are not expected to be effective against disease caused by other filoviruses. A meeting of subject-matter experts was held during the 10th International Filovirus Symposium to discuss strategies to address these gaps. Several investigational therapeutics, vaccine candidates, and combination strategies were presented. The greatest challenge was identified to be the implementation of well-designed clinical trials of safety and efficacy during filovirus disease outbreaks. Preparing for this will require agreed-upon common protocols for trials intended to bridge multiple outbreaks across all at-risk countries. A multinational research consortium including at-risk countries would be an ideal mechanism to negotiate agreement on protocol design and coordinate preparation. Discussion participants recommended a follow-up meeting be held in Africa to establish such a consortium.Although there are now approved treatments and vaccines for Ebola virus disease, the case fatality rate remains unacceptably high even when patients are treated with the newly approved therapeutics. Furthermore, these countermeasures are not expected to be effective against disease caused by other filoviruses. A meeting of subject-matter experts was held during the 10th International Filovirus Symposium to discuss strategies to address these gaps. Several investigational therapeutics, vaccine candidates, and combination strategies were presented. The greatest challenge was identified to be the implementation of well-designed clinical trials of safety and efficacy during filovirus disease outbreaks. Preparing for this will require agreed-upon common protocols for trials intended to bridge multiple outbreaks across all at-risk countries. A multinational research consortium including at-risk countries would be an ideal mechanism to negotiate agreement on protocol design and coordinate preparation. Discussion participants recommended a follow-up meeting be held in Africa to establish such a consortium.
Abstract Although there are now approved treatments and vaccines for Ebola virus disease, the case fatality rate remains unacceptably high even when patients are treated with the newly approved therapeutics. Furthermore, these countermeasures are not expected to be effective against disease caused by other filoviruses. A meeting of subject-matter experts was held during the 10th International Filovirus Symposium to discuss strategies to address these gaps. Several investigational therapeutics, vaccine candidates, and combination strategies were presented. The greatest challenge was identified to be the implementation of well-designed clinical trials of safety and efficacy during filovirus disease outbreaks. Preparing for this will require agreed-upon common protocols for trials intended to bridge multiple outbreaks across all at-risk countries. A multinational research consortium including at-risk countries would be an ideal mechanism to negotiate agreement on protocol design and coordinate preparation. Discussion participants recommended a follow-up meeting be held in Africa to establish such a consortium.
Author Kobinger, Gary
Feldmann, Heinz
Muyembe, Jean-Jacques
Spiropoulou, Christina F
Martins, Karen A
Cross, Robert
Nyhuis, Tara
Woolsey, Courtney
Ahuka-Mundeke, Steve
Cihlar, Tomas
Strong, Jim
Geisbert, Thomas W
Montgomery, Joel M
Crozier, Ian
Sprecher, Armand
Marzi, Andrea
Wolfe, Daniel
Teicher, Carrie
Author_xml – sequence: 1
  givenname: Armand
  surname: Sprecher
  fullname: Sprecher, Armand
  email: armand.sprecher@brussels.msf.org
– sequence: 2
  givenname: Robert
  surname: Cross
  fullname: Cross, Robert
– sequence: 3
  givenname: Andrea
  orcidid: 0000-0003-0186-9587
  surname: Marzi
  fullname: Marzi, Andrea
– sequence: 4
  givenname: Karen A
  surname: Martins
  fullname: Martins, Karen A
– sequence: 5
  givenname: Daniel
  surname: Wolfe
  fullname: Wolfe, Daniel
– sequence: 6
  givenname: Joel M
  orcidid: 0000-0003-0523-4431
  surname: Montgomery
  fullname: Montgomery, Joel M
– sequence: 7
  givenname: Christina F
  surname: Spiropoulou
  fullname: Spiropoulou, Christina F
– sequence: 8
  givenname: Tomas
  surname: Cihlar
  fullname: Cihlar, Tomas
– sequence: 9
  givenname: Steve
  surname: Ahuka-Mundeke
  fullname: Ahuka-Mundeke, Steve
– sequence: 10
  givenname: Tara
  surname: Nyhuis
  fullname: Nyhuis, Tara
– sequence: 11
  givenname: Carrie
  surname: Teicher
  fullname: Teicher, Carrie
– sequence: 12
  givenname: Ian
  surname: Crozier
  fullname: Crozier, Ian
– sequence: 13
  givenname: Jim
  surname: Strong
  fullname: Strong, Jim
– sequence: 14
  givenname: Gary
  surname: Kobinger
  fullname: Kobinger, Gary
– sequence: 15
  givenname: Courtney
  surname: Woolsey
  fullname: Woolsey, Courtney
– sequence: 16
  givenname: Thomas W
  surname: Geisbert
  fullname: Geisbert, Thomas W
– sequence: 17
  givenname: Heinz
  orcidid: 0000-0001-9448-8227
  surname: Feldmann
  fullname: Feldmann, Heinz
– sequence: 18
  givenname: Jean-Jacques
  surname: Muyembe
  fullname: Muyembe, Jean-Jacques
BackLink https://www.ncbi.nlm.nih.gov/pubmed/37596837$$D View this record in MEDLINE/PubMed
BookMark eNqFkc1rFEEQxRuJmE3i1aM0eDGHTbq7er68hdXVQIJB9Dx099RILzPdY38s-N-nZdccAuKpKN7vVRX1zsiJ8w4JecPZFWcdXFs3DjZe76waoJIvyIpX0KzrmsMJWTEmxJq3XXdKzmLcMcYk1M0rcgpN1dUtNCuiHzDEBU2ye4zUO3oz7JUz1v2kG59dwjCjijkUcfSBbu3k9zbkSD_aWAT8QL_h4kOi2-Bnquh9nlJRTCrwPWIqgy7Iy1FNEV8f6zn5sf30ffNlfff18-3m5m5toGtSuVkKo2EchTRCKAY1KgRTOl0NQito66aRyPQIEkStJdO6qjhDbPWAxsA5eX-YuwT_K2NM_WyjwWlSDn2OvWgr6GQrGl7Qd8_Qnc_Blet6YJKzumMcCvX2SGU949Avwc4q_O7_fq8AVwfABB9jwPEJ4az_E09_iKc_xlMM8pnB2KSS9S4FZad_2y4PNp-X_614BLOmpjU
CitedBy_id crossref_primary_10_1016_S2214_109X_24_00255_9
crossref_primary_10_18699_SSMJ20240602
Cites_doi 10.1093/cid/ciac732
10.3390/vaccines10111935
10.1038/s41467-021-22132-0
10.1056/NEJMoa1910993
10.1016/S2666-5247(23)00001-0
10.1038/nrd.2017.251
10.1172/jci.insight.159090
10.3390/vaccines10071004
10.1016/S0140-6736(16)32621-6
10.1093/cid/ciab215
10.1097/MS9.0000000000000596
10.1016/j.infpip.2020.100038
10.1016/S1473-3099(23)00344-4
10.3390/vaccines9030190
10.1016/j.chom.2018.12.005
10.1126/scitranslmed.aai8711
10.3390/vaccines10101582
10.1093/infdis/jiad157
ContentType Journal Article
Copyright Published by Oxford University Press on behalf of Infectious Diseases Society of America 2023. 2023
Published by Oxford University Press on behalf of Infectious Diseases Society of America 2023.
Copyright_xml – notice: Published by Oxford University Press on behalf of Infectious Diseases Society of America 2023. 2023
– notice: Published by Oxford University Press on behalf of Infectious Diseases Society of America 2023.
DBID AAYXX
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
K9.
NAPCQ
7X8
DOI 10.1093/infdis/jiad354
DatabaseName CrossRef
Medline
MEDLINE
MEDLINE (Ovid)
MEDLINE
MEDLINE
PubMed
ProQuest Health & Medical Complete (Alumni)
ProQuest Nursing and Allied Health Premium
MEDLINE - Academic
DatabaseTitle CrossRef
MEDLINE
Medline Complete
MEDLINE with Full Text
PubMed
MEDLINE (Ovid)
ProQuest Health & Medical Complete (Alumni)
Nursing & Allied Health Premium
MEDLINE - Academic
DatabaseTitleList MEDLINE
MEDLINE - Academic
CrossRef

ProQuest Health & Medical Complete (Alumni)
Database_xml – sequence: 1
  dbid: NPM
  name: PubMed
  url: https://proxy.k.utb.cz/login?url=http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?db=PubMed
  sourceTypes: Index Database
– sequence: 2
  dbid: EIF
  name: MEDLINE
  url: https://proxy.k.utb.cz/login?url=https://www.webofscience.com/wos/medline/basic-search
  sourceTypes: Index Database
DeliveryMethod fulltext_linktorsrc
Discipline Medicine
Biology
DocumentTitleAlternate 10th International Symposium on Filoviruses
EISSN 1537-6613
EndPage S478
ExternalDocumentID 37596837
10_1093_infdis_jiad354
10.1093/infdis/jiad354
Genre Journal Article
Research Support, N.I.H., Extramural
GeographicLocations Africa
GeographicLocations_xml – name: Africa
GrantInformation_xml – fundername: NIH HHS
  grantid: 75N91019D00024
– fundername: NCI NIH HHS
  grantid: 75N91019D00024
GroupedDBID ---
-DZ
-~X
..I
.2P
.55
.GJ
.I3
.XZ
.ZR
08P
0R~
123
1KJ
1TH
29K
2AX
2WC
36B
3O-
4.4
41~
48X
53G
5GY
5RE
5VS
5WD
70D
85S
AABZA
AACGO
AACZT
AAHBH
AAHTB
AAJKP
AAJQQ
AAMVS
AANCE
AAOGV
AAPGJ
AAPNW
AAPQZ
AAPXW
AAQQT
AARHZ
AAUAY
AAUQX
AAVAP
AAWDT
AAWTL
AAYOK
ABBHK
ABDFA
ABDPE
ABEJV
ABEUO
ABGNP
ABIXL
ABJNI
ABKDP
ABLJU
ABNHQ
ABNKS
ABOCM
ABPEJ
ABPLY
ABPPZ
ABPQP
ABPTD
ABQLI
ABQNK
ABSMQ
ABTLG
ABVGC
ABWST
ABXSQ
ABXVV
ABZBJ
ACFRR
ACGFO
ACGFS
ACGOD
ACHIC
ACPQN
ACPRK
ACUFI
ACUTJ
ACUTO
ACVCV
ACYHN
ACZBC
ADBBV
ADEYI
ADGZP
ADHKW
ADHZD
ADIPN
ADMTO
ADNBA
ADOCK
ADQBN
ADQXQ
ADRTK
ADULT
ADVEK
ADYVW
ADZXQ
AEGPL
AEGXH
AEJOX
AEKPW
AEKSI
AEMDU
AEMQT
AENEX
AENZO
AEPUE
AETBJ
AEUPB
AEWNT
AEXZC
AFFNX
AFFQV
AFFZL
AFHKK
AFIYH
AFOFC
AFQQW
AFSHK
AFXAL
AFYAG
AGINJ
AGKEF
AGKRT
AGMDO
AGQXC
AGSYK
AGUTN
AHMBA
AHMMS
AHXPO
AI.
AIAGR
AIJHB
AJDVS
AJEEA
AJNCP
ALMA_UNASSIGNED_HOLDINGS
ALUQC
ALXQX
APIBT
APJGH
APWMN
AQDSO
AQKUS
AQVQM
ATGXG
AVNTJ
AXUDD
BAWUL
BAYMD
BCRHZ
BEYMZ
BHONS
BR6
BTRTY
BVRKM
BZKNY
C45
CDBKE
CS3
CZ4
D-I
DAKXR
DCCCD
DIK
DILTD
DU5
D~K
EBS
ECGQY
EE~
EIHJH
EJD
EMOBN
ENERS
F5P
F9B
FECEO
FLUFQ
FOEOM
FOTVD
FQBLK
GAUVT
GJXCC
GX1
H13
H5~
HAR
HQ3
HTVGU
HW0
HZ~
IH2
IOX
IPSME
J21
J5H
JAAYA
JBMMH
JENOY
JHFFW
JKQEH
JLS
JLXEF
JPM
JSG
JST
JXSIZ
KAQDR
KBUDW
KOP
KQ8
KSI
KSN
L7B
LSO
LU7
M49
MBLQV
MHKGH
MJL
ML0
MVM
N4W
N9A
NEJ
NGC
NOMLY
NOYVH
NU-
NVLIB
O0~
O9-
OAUYM
OAWHX
OBFPC
OCZFY
ODMLO
OJQWA
OJZSN
OK1
OPAEJ
OVD
OWPYF
O~Y
P0-
P2P
PAFKI
PEELM
PQQKQ
Q1.
Q5Y
QBD
RD5
ROX
ROZ
RUSNO
RW1
RXO
SA0
SJN
TCURE
TEORI
TJX
TMA
TR2
VH1
W2D
W8F
WH7
X7H
X7M
Y6R
YAYTL
YKOAZ
YXANX
ZE2
ZGI
ZKG
ZXP
~91
AAYXX
AGORE
AHGBF
AJBYB
CITATION
CGR
CUY
CVF
ECM
EIF
NPM
K9.
NAPCQ
7X8
ID FETCH-LOGICAL-c397t-6642cb3ff24c22a036eae3c24cb5d2ba386774e0bf34326b40bb5510ee8bdecc3
ISSN 0022-1899
1537-6613
IngestDate Fri Jul 11 16:12:34 EDT 2025
Mon Jun 30 10:54:17 EDT 2025
Thu Apr 03 07:04:50 EDT 2025
Tue Jul 01 01:31:38 EDT 2025
Thu Apr 24 22:59:29 EDT 2025
Wed Apr 02 07:06:43 EDT 2025
IsDoiOpenAccess false
IsOpenAccess true
IsPeerReviewed true
IsScholarly true
Issue Supplement_7
Keywords therapeutics
disease outbreaks
clinical trials
filoviruses
vaccines
Language English
License This work is written by (a) US Government employee(s) and is in the public domain in the US.
Published by Oxford University Press on behalf of Infectious Diseases Society of America 2023.
LinkModel OpenURL
MergedId FETCHMERGED-LOGICAL-c397t-6642cb3ff24c22a036eae3c24cb5d2ba386774e0bf34326b40bb5510ee8bdecc3
Notes ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 14
content type line 23
ORCID 0000-0003-0186-9587
0000-0003-0523-4431
0000-0001-9448-8227
OpenAccessLink https://academic.oup.com/jid/advance-article-pdf/doi/10.1093/infdis/jiad354/51173618/jiad354.pdf
PMID 37596837
PQID 3041069013
PQPubID 41591
ParticipantIDs proquest_miscellaneous_2853948271
proquest_journals_3041069013
pubmed_primary_37596837
crossref_primary_10_1093_infdis_jiad354
crossref_citationtrail_10_1093_infdis_jiad354
oup_primary_10_1093_infdis_jiad354
ProviderPackageCode CITATION
AAYXX
PublicationCentury 2000
PublicationDate 2023-11-15
PublicationDateYYYYMMDD 2023-11-15
PublicationDate_xml – month: 11
  year: 2023
  text: 2023-11-15
  day: 15
PublicationDecade 2020
PublicationPlace United States
PublicationPlace_xml – name: United States
– name: Oxford
PublicationTitle The Journal of infectious diseases
PublicationTitleAlternate J Infect Dis
PublicationYear 2023
Publisher Oxford University Press
Publisher_xml – name: Oxford University Press
References Bornholdt (2023111521055128000_jiad354-B7) 2019; 25
Gilead Sciences (2023111521055128000_jiad354-B23) 2023
Wohl (2023111521055128000_jiad354-B4) 2023; 76
Cao (2023111521055128000_jiad354-B12) 2023
Henao-Restrepo (2023111521055128000_jiad354-B17) 2017; 389
Cooper (2023111521055128000_jiad354-B10) 2022; 10
Finch (2023111521055128000_jiad354-B14) 2022; 10
International AIDS Vaccine Initiative (2023111521055128000_jiad354-B9) 2022
Aderinto (2023111521055128000_jiad354-B28) 2023; 85
Mackman (2023111521055128000_jiad354-B21) 2023
Mwesigwa (2023111521055128000_jiad354-B18) 2023
Cross (2023111521055128000_jiad354-B20) 2021; 12
Centers for Disease Control and Prevention (2023111521055128000_jiad354-B2) 2023
Mulangu (2023111521055128000_jiad354-B3) 2019; 381
Marzi (2023111521055128000_jiad354-B13) 2023; 4
Woolsey (2023111521055128000_jiad354-B15) 2023; 228
Anoshchenko (2023111521055128000_jiad354-B22)
Cross (2023111521055128000_jiad354-B19) 2022; 7
Krause (2023111521055128000_jiad354-B27) 2023
Shears (2023111521055128000_jiad354-B29) 2020; 2
Cross (2023111521055128000_jiad354-B16) 2018; 17
Zhu (2023111521055128000_jiad354-B11) 2022; 10
Mire (2023111521055128000_jiad354-B8) 2017; 9
Higgs (2023111521055128000_jiad354-B5) 2021; 73
Wolf (2023111521055128000_jiad354-B6) 2021; 9
World Health Organization (2023111521055128000_jiad354-B26) 2022
Gilead Sciences (2023111521055128000_jiad354-B24) 2023
Centers for Disease Control and Prevention (2023111521055128000_jiad354-B1) 2023
US Embassy in Uganda (2023111521055128000_jiad354-B25) 2022
References_xml – volume: 76
  start-page: e835
  year: 2023
  ident: 2023111521055128000_jiad354-B4
  article-title: Post-Ebola symptoms 7 years after infection: the natural history of long Ebola
  publication-title: Clin Infect Dis
  doi: 10.1093/cid/ciac732
– volume: 10
  start-page: 1935
  year: 2022
  ident: 2023111521055128000_jiad354-B14
  article-title: Single-shot ChAd3-MARV vaccine in modified formulation buffer shows 100% protection of NHPs
  publication-title: Vaccines (Basel)
  doi: 10.3390/vaccines10111935
– volume: 12
  start-page: 1891
  year: 2021
  ident: 2023111521055128000_jiad354-B20
  article-title: Combination therapy protects macaques against advanced Marburg virus disease
  publication-title: Nat Commun
  doi: 10.1038/s41467-021-22132-0
– volume: 381
  start-page: 2293
  year: 2019
  ident: 2023111521055128000_jiad354-B3
  article-title: A randomized, controlled trial of Ebola virus disease therapeutics
  publication-title: N Engl J Med
  doi: 10.1056/NEJMoa1910993
– volume: 4
  start-page: e171
  year: 2023
  ident: 2023111521055128000_jiad354-B13
  article-title: Species-specific immunogenicity and protective efficacy of a vesicular stomatitis virus–based Sudan virus vaccine: a challenge study in macaques
  publication-title: Lancet Microbe
  doi: 10.1016/S2666-5247(23)00001-0
– volume: 17
  start-page: 413
  year: 2018
  ident: 2023111521055128000_jiad354-B16
  article-title: Post-exposure treatments for Ebola and Marburg virus infections
  publication-title: Nat Rev Drug Discov
  doi: 10.1038/nrd.2017.251
– year: 2022
  ident: 2023111521055128000_jiad354-B9
– volume: 7
  start-page: e159090
  year: 2022
  ident: 2023111521055128000_jiad354-B19
  article-title: Combination therapy with remdesivir and monoclonal antibodies protects nonhuman primates against advanced Sudan virus disease
  publication-title: JCI Insight
  doi: 10.1172/jci.insight.159090
– volume: 10
  start-page: 1004
  year: 2022
  ident: 2023111521055128000_jiad354-B11
  article-title: A cloned recombinant vesicular stomatitis virus–vectored Marburg vaccine, PHV01, protects guinea pigs from lethal Marburg virus disease
  publication-title: Vaccines (Basel)
  doi: 10.3390/vaccines10071004
– volume: 389
  start-page: 505
  year: 2017
  ident: 2023111521055128000_jiad354-B17
  article-title: Efficacy and effectiveness of an rVSV-vectored vaccine in preventing Ebola virus disease: final results from the Guinea ring vaccination, open-label, cluster-randomised trial (Ebola Ça Suffit!)
  publication-title: Lancet
  doi: 10.1016/S0140-6736(16)32621-6
– volume: 73
  start-page: 1849
  year: 2021
  ident: 2023111521055128000_jiad354-B5
  article-title: PREVAIL IV: a randomized, double-blind, 2-phase, phase 2 trial of remdesivir vs placebo for reduction of Ebola virus RNA in the semen of male survivors
  publication-title: Clin Infect Dis
  doi: 10.1093/cid/ciab215
– ident: 2023111521055128000_jiad354-B22
– volume: 85
  start-page: 2247
  year: 2023
  ident: 2023111521055128000_jiad354-B28
  article-title: A reflection on the Marburg virus outbreak in Tanzania: the importance of preparedness and prevention in public health—a correspondence
  publication-title: Ann Med Surg (Lond)
  doi: 10.1097/MS9.0000000000000596
– start-page: 91
  volume-title: NPJ Vaccines
  year: 2023
  ident: 2023111521055128000_jiad354-B12
– volume: 2
  start-page: 100038
  year: 2020
  ident: 2023111521055128000_jiad354-B29
  article-title: The 2018/19 Ebola epidemic the Democratic Republic of the Congo (DRC): epidemiology, outbreak control, and conflict
  publication-title: Infect Prev Pract
  doi: 10.1016/j.infpip.2020.100038
– start-page: S1473-3099(23)00344-4
  year: 2023
  ident: 2023111521055128000_jiad354-B18
  article-title: Safety, tolerability, and immunogenicity of the Ebola Sudan chimpanzee adenovirus vector vaccine (cAd3-EBO S) in healthy Ugandan adults: a phase 1, open-label, dose-escalation clinical trial
  publication-title: Lancet Infect Dis
  doi: 10.1016/S1473-3099(23)00344-4
– volume: 9
  start-page: 190
  year: 2021
  ident: 2023111521055128000_jiad354-B6
  article-title: Development of pandemic vaccines: ERVEBO case study
  publication-title: Vaccines (Basel)
  doi: 10.3390/vaccines9030190
– year: 2023
  ident: 2023111521055128000_jiad354-B27
– start-page: 1891.
  volume-title: J Med Chem
  year: 2023
  ident: 2023111521055128000_jiad354-B21
– year: 2022
  ident: 2023111521055128000_jiad354-B25
– volume: 25
  start-page: 49
  year: 2019
  ident: 2023111521055128000_jiad354-B7
  article-title: A two-antibody pan-ebolavirus cocktail confers broad therapeutic protection in ferrets and nonhuman primates
  publication-title: Cell Host Microbe
  doi: 10.1016/j.chom.2018.12.005
– year: 2023
  ident: 2023111521055128000_jiad354-B1
– volume: 9
  start-page: eaai8711
  year: 2017
  ident: 2023111521055128000_jiad354-B8
  article-title: Therapeutic treatment of Marburg and Ravn virus infection in nonhuman primates with a human monoclonal antibody
  publication-title: Sci Transl Med
  doi: 10.1126/scitranslmed.aai8711
– year: 2023
  ident: 2023111521055128000_jiad354-B23
– volume: 10
  start-page: 1582
  year: 2022
  ident: 2023111521055128000_jiad354-B10
  article-title: Nonhuman primates are protected against Marburg virus disease by vaccination with a vesicular stomatitis virus vector–based vaccine prepared under conditions to allow advancement to human clinical trials
  publication-title: Vaccines (Basel)
  doi: 10.3390/vaccines10101582
– volume: 228
  year: 2023
  ident: 2023111521055128000_jiad354-B15
  article-title: A highly attenuated panfilovirus VesiculoVax vaccine rapidly protects nonhuman primates against Marburg virus and 3 species of Ebola virus
  publication-title: J Infect Dis
  doi: 10.1093/infdis/jiad157
– year: 2022
  ident: 2023111521055128000_jiad354-B26
– year: 2023
  ident: 2023111521055128000_jiad354-B24
– year: 2023
  ident: 2023111521055128000_jiad354-B2
SSID ssj0004367
Score 2.4603734
Snippet Abstract Although there are now approved treatments and vaccines for Ebola virus disease, the case fatality rate remains unacceptably high even when patients...
Although there are now approved treatments and vaccines for Ebola virus disease, the case fatality rate remains unacceptably high even when patients are...
SourceID proquest
pubmed
crossref
oup
SourceType Aggregation Database
Index Database
Enrichment Source
Publisher
StartPage S474
SubjectTerms Africa
Clinical trials
Disease Outbreaks - prevention & control
Ebola virus
Ebolavirus
Filoviridae
Filoviridae Infections
Hemorrhagic Fever, Ebola - epidemiology
Hemorrhagic Fever, Ebola - prevention & control
Humans
Outbreaks
Vaccines
Title Perspectives on Advancing Countermeasures for Filovirus Disease: Report From a Multisector Meeting
URI https://www.ncbi.nlm.nih.gov/pubmed/37596837
https://www.proquest.com/docview/3041069013
https://www.proquest.com/docview/2853948271
Volume 228
hasFullText 1
inHoldings 1
isFullTextHit
isPrint
link http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV3db9MwELfKEIgXBANGYSCDkHiosiW2k6a8TWhlQutAWiv1LfJXpKItndoUif0d_MGcP-JkMMbHS9S40aX1nc_nu_vdIfSGyZKLWMmI8FhELE11xEUuI6lEIrVBDdjWCZOT7GjGPs7Tea_3vZO1tKnFnry8FlfyP1yFMeCrQcn-A2cDURiAz8BfuAKH4fpXPP7cIiWt19-2SJYukr8xM3buPIC25sJgvDhbfl2sNmtTctNEZVwynDHAwX5dng_4wMJx19aRP5hoi4buWq8tjsyXmnCJXEDRx3mCgX56AZrUi8OBwSWoEOxo-rS7nO7WI766XIQMS94Zrr1H3MLWvOvVuykINXg9B9S8Cf7YVc1wKk5y1y1pTzfaeBiBAUG76pp4MLlTuKfMNfnxmzfc5tduDK5oFgwpU7ph_GXBFU1Zuwk2gf-TT8V4dnxcTA_n01voNoHDh-mL8WHeJg4xmg2bGvTmB4dSoHTf0d_31K-YOlfgk7-cYqw1M32A7nsm4gMnUw9RT1fb6I5rTPptG92d-JSLR0h0hQwvKxyEDP8kZBjmHgchw17I3mEnYtiIGOa4I2LYi9hjNBsfTt8fRb4xRyTBfK2BJYxIQcuSMElgkdNMc00l3IlUEcGpKZLIdCxKA1vOBIuFAMs81joXCnQGfYK2qmWlnyKsmSI6EXSoFGdZHguZlzFoCwU0R2B791HUzGEhfdV60zzlrHDZE7Rwc174Oe-jt-H5C1ev5bdPvgaW_PGh3YZjhV_464LGLDEFvhPaR6_C16CWTayNVxqWXUHADB6ZErvwD3Ycp8Or6DAdZTkdPruZ-HN0r11Iu2irXm30C7CAa_HSCuQP0LK6ZQ
linkProvider Geneva Foundation for Medical Education and Research
openUrl ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=Perspectives+on+Advancing+Countermeasures+for+Filovirus+Disease%3A+Report+From+a+Multisector+Meeting&rft.jtitle=The+Journal+of+infectious+diseases&rft.au=Sprecher%2C+Armand&rft.au=Cross%2C+Robert&rft.au=Marzi%2C+Andrea&rft.au=Martins%2C+Karen+A&rft.date=2023-11-15&rft.pub=Oxford+University+Press&rft.issn=0022-1899&rft.eissn=1537-6613&rft.volume=228&rft.spage=S474&rft.epage=S478&rft_id=info:doi/10.1093%2Finfdis%2Fjiad354&rft.externalDBID=NO_FULL_TEXT
thumbnail_l http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0022-1899&client=summon
thumbnail_m http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0022-1899&client=summon
thumbnail_s http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0022-1899&client=summon